Search

Displaying results 3361 - 3370 of 10000 in total
  1. Drug

    Nadecnemab

    go.drugbank.com/drugs/DB16677
    Investigational

    Nadecnemab is under investigation in clinical trial NCT03956550 (A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee).

  2. Drug

    Anti-inhibitor coagulant complex

    go.drugbank.com/drugs/DB13151
    ApprovedInvestigational

    It is used to control bleeding in hemophilia A and B patients with inhibitors. … Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.

    Products: FEIBA 500 U, FEIBA 1000 U
  3. Drug

    Mazindol

    go.drugbank.com/drugs/DB00579
    Approved

    Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.

  4. Drug

    Lesinurad

    go.drugbank.com/drugs/DB11560
    ApprovedWithdrawn

    Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target … In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with

  5. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious

  6. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    in severe systemic copper deficiency. … [A275383,T903] In patients with the disease, defects in this transporter lead to the entrapment of copper in the intestinal lining and a subsequent inability to absorb it into the bloodstream, resulting

  7. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Elbimilast

    go.drugbank.com/drugs/DB20663
    Investigational

    Elbimilast is under investigation in clinical trial NCT00977886 (Safety and Pharmacokinetics of ELB353 in Healthy Men). Elbimilast has a monoisotopic molecular weight of 442.04 Da. … The usage of the INN stem '-milast' in the name indicates that Elbimilast is a Phosphodiesterase-4 (PDE4) inhibitor.

  9. Drug

    Bleselumab

    go.drugbank.com/drugs/DB15253
    Investigational

    Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney

  10. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

    Synonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)